Mark E. Boye

1.2k citations

40 papers · 851 indexed · h-index 18

Impact in

Statistics and Probability top 2%
- Statistical Methods and Bayesian Inference
- Statistical Methods and Inference
Anesthesiology and Pain Medicine top 5%
- Pain Management and Opioid Use

Papers in ⓘ

Statistics and Probability 6
- Statistical Methods and Inference 4
Anesthesiology and Pain Medicine 3

Co-authors: Joseph G. Ibrahim (6 shared papers)Wei Shen (5 shared papers)Jack Mardekian (1 shared paper)Mani Lakshminarayanan (1 shared paper)Mark P. Jensen (1 shared paper)Danjie Zhang (5 shared papers)Ming‐Hui Chen (3 shared papers)Stanley Lemeshow (1 shared paper)
Journals: Value in Health (5 papers)Journal of Clinical Oncology (4 papers)Anesthesiology (2 papers)Statistics in Medicine (2 papers)PharmacoEconomics (1 paper)
Partner nations: United States United Kingdom South Korea

In The Last Decade

Mark E. Boye

36 papers receiving 829 citations

Peers

Countries citing papers authored by Mark E. Boye

Since Specialization

Citations

This map shows the geographic impact of Mark E. Boye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Boye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Boye more than expected).

Fields of papers citing papers by Mark E. Boye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Boye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Boye. The network helps show where Mark E. Boye may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark E. Boye, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark E. Boye Line = papers co-authored together Mark E. Boye links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Safety and Efficacy of the Cyclooxygenase-2 Inhibitors Parecoxib and Valdecoxib after Noncardiac Surgery Anesthesiology ·Nancy A. Nussmeier, Andrew Whelton, Mark T. Brown, Girish P. Joshi, Richard Langford, Neil Singla, Mark E. Boye, Kenneth M. Verburg	2006	116
2	Joint modeling of survival and longitudinal non‐survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group Statistics in Medicine ·A. Lawrence Gould, Mark E. Boye, Michael J. Crowther, Joseph G. Ibrahim, George Quartey, Sandrine Micallef, Frédéric Y. Bois	2014	92
3	Validity of 24-h recall ratings of pain severity: Biasing effects of “Peak” and “End” pain Pain ·Mark P. Jensen, Jack Mardekian, Mani Lakshminarayanan, Mark E. Boye	2007	74
4	Delays in receipt of immunizations in low-birth-weight children: a nationally representative sample. PubMed ·Diane L. Langkamp, Stacy Hoshaw‐Woodard, Mark E. Boye, Stanley Lemeshow	2001	68
5	KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis Cancer Treatment and Research Communications ·Rebecca Goulding, Matthew Chenoweth, Gebra Cuyún Carter, Mark E. Boye, Kristin M. Sheffield, William J. John, Mark S. Leusch, Catherine E. Muehlenbein, Li Li, Min‐Hua Jen, Adina Rojubally, Jeroen J. Jansen, Eric Druyts	2020	49
6	The economic burden of metastatic breast cancer: A systematic review of literature from developed countries Cancer Treatment Reviews ·Talia Foster, Jeffrey D. Miller, Mark E. Boye, M Blieden, Risha Gidwani, Mason W. Russell	2011	49
7	`JMFit`: ASASMacro for Joint Models of Longitudinal and Survival Data Journal of Statistical Software ·Danjie Zhang, Ming‐Hui Chen, Joseph G. Ibrahim, Mark E. Boye, Wei Shen	2016	35
8	Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials Statistics in Medicine ·Danjie Zhang, Ming‐Hui Chen, Joseph G. Ibrahim, Mark E. Boye, Ping Wang, Wei Shen	2014	33
9	An Evaluation of the Pharmacy College Admissions Test as a Tool for Pharmacy College Admissions Committees American Journal of Pharmaceutical Education ·Katherine A. Kelley, Kristina Secnik, Mark E. Boye	2001	31
10	Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes With Many Zeros Journal of the American Statistical Association ·Laura A. Hatfield, Mark E. Boye, Michelle D. Hackshaw, Bradley P. Carlin	2012	31
11	Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma Leukemia & lymphoma ·Christiane Querfeld, Timothy M. Kuzel, Youn H. Kim, Pierluigi Porcu, Madeleine Duvic, Amy Musiek, Alain H. Rook, Lawrence A. Mark, Lauren Pinter‐Brown, Oday Hamid, Boris K. Lin, Ying Bian, Mark E. Boye, Jeannette M. Day, Steven T. Rosen	2011	29
12	Parecoxib, propacetamol, and their combination for analgesia after total hip arthroplasty: a randomized non‐inferiority trial Acta Anaesthesiologica Scandinavica ·F. Camu, Alain Borgeat, R. Heylen, É. Viel, Mark E. Boye, Raymond Cheung	2016	27
13	Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data With Applications to Cancer Clinical Trials Journal of Computational and Graphical Statistics ·Danjie Zhang, Ming‐Hui Chen, Joseph G. Ibrahim, Mark E. Boye, Wei Shen	2015	26
14	Joint Modeling of Multiple Longitudinal Patient-Reported Outcomes and Survival Journal of Biopharmaceutical Statistics ·Laura A. Hatfield, Mark E. Boye, Bradley P. Carlin	2011	26
15	Direct Medical Costs for Complications Among Children and Adults with Diabetes in the US Commercial Payer Setting Applied Health Economics and Health Policy ·Jason Yeaw, Shawn Halinan, Dionne M. Hines, Amy M. DeLozier, M. Perez, Mark E. Boye, Kristina S. Boye, Christopher M. Blanchette	2014	25
16	Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial Health Services and Outcomes Research Methodology ·Ping Wang, Wei Shen, Mark E. Boye	2012	21
17	Economic Burden of Follicular Non-Hodgkinʼs Lymphoma PharmacoEconomics ·Talia Foster, Jeffrey D. Miller, Mark E. Boye, Mason W. Russell	2009	19
18	Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer ·Gayathri Kumar, Beth Woods, Lisa M. Hess, Joseph Treat, Mark E. Boye, Peter Bryden, Katherine B. Winfree	2015	17
19	Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN) Annals of Oncology ·Coleman K. Obasaju, Lee Bowman, P. Wang, Wei Shen, Katherine B. Winfree, Emily Nash Smyth, Mark E. Boye, William J. John, Thomas Brodowicz, Chandra P. Belani	2013	16
20	First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial Clinical Lung Cancer ·Mark E. Boye, Xin Wang, Vichien Srimuninnimit, Jin Hyoung Kang, Chun‐Ming Tsai, Mauro Orlando, Tarun Puri, Jong Seok Kim, Narayan Rajan, James Chih‐Hsin Yang	2015	13

About Mark E. Boye

Mark E. Boye is a scholar working on Statistics and Probability, Anesthesiology and Pain Medicine, Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics, having authored 40 papers that have together received 851 indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (8 papers), Lung Cancer Treatments and Mutations (7 papers), Cancer Treatment and Pharmacology (4 papers), Statistical Methods and Inference (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Advanced Breast Cancer Therapies (4 papers), Cardiac, Anesthesia and Surgical Outcomes (3 papers) and Anesthesia and Pain Management (3 papers). The work is most often cited by research in Statistics and Probability (156 citations), Anesthesiology and Pain Medicine (77 citations), Pharmacology (110 citations), Oncology (141 citations) and Pulmonary and Respiratory Medicine (157 citations). Mark E. Boye has collaborated with scholars based in United States, United Kingdom and South Korea. Frequent co-authors include Joseph G. Ibrahim, Wei Shen, Jack Mardekian, Mani Lakshminarayanan, Mark P. Jensen, Danjie Zhang, Ming‐Hui Chen, Stanley Lemeshow, Stacy Hoshaw‐Woodard and Diane L. Langkamp. Their work appears in journals such as Value in Health, Journal of Clinical Oncology, Anesthesiology, Statistics in Medicine and PharmacoEconomics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact